LULU, AVGO, DELL, SNOW, GOOGL: 5 Stocks Investors Couldn't Stop Buzzing About This Week
Retail investors talked up 5 hot stocks during the week (Aug. 31 to Sept. 4) on X and Reddit's r/WallStreetBets: AVGO, LULU, DELL, SNOW, GOOG.
Stocks · News reference
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions
A congresswoman recently bought stocks connected to Warren Buffett and Elon Musk.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
GSK's Specialty Medicines segment, accounting for over 40% of sales, grew 14% in H1 2026 driven by HIV, respiratory, and oncology products. The company is accelerating R&D with over 20 phase III starts planned for 2026. However, GSK faces a significant challenge as dolutegravir patents expire in 2028-2029, threatening its HIV franchise which generated £2.74 billion in H1 2026. GSK is relying on long-acting HIV injectables and next-generation pipeline products to offset future generic competition.
Recent Filing Shows That Rep. Maria Elvira Salazar Bought Over $34K Worth of Merck & Co Stock
September 9, 2026 records indicate that Representative Maria Elvira Salazar filed a purchase of Merck & Co (NYSE:MRK), valued between $34,006 and $160,000. According to the September filing, the transaction occurred
HSBC Maintains Buy on Merck & Co, Raises Price Target to $172
HSBC analyst Rajesh Kumar maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $150 to $172.
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
Merck's stock is trading near its 52-week high, driven by positive phase III data for its Keytruda-Moderna cancer therapy combo and strong fundamentals. Keytruda is expected to reach $35 billion in peak sales by 2028, with the company launching 20 new drugs by 2030. However, Merck faces significant headwinds including Keytruda's 2028 patent expiration, declining Gardasil vaccine sales, and generic erosion of diabetes and other drugs.
SpaceX Trades at 98 Times Sales. Here's What Amazon's Multiple Looked Like at the Same Stage.
SpaceX trades at a price-to-sales ratio of 98 with a $2.1 trillion market cap on $23 billion in revenue. The article compares this to Amazon in 2009, when it had similar revenue but traded at a P/S ratio of only 1.5-2.5 while being more profitable. The analysis suggests that even if SpaceX reaches $1 trillion in revenue by 2030, the stock may not appreciate significantly from current levels, and a P/S compression to Amazon's 2009 levels could result in substantial losses.